Sign in

    Eric Fleming

    Senior Research Associate at Raymond James

    Eric Fleming is a Senior Research Associate at Raymond James Financial specializing in healthcare sector research. He has developed expertise in analyzing companies across the healthcare industry, contributing to in-depth equity research coverage for institutional clients. Fleming began his career in finance after previous experience in data analytics at SPX FLOW and joined Raymond James prior to 2024, leveraging both technical and sector-specific skills as part of the research team. He holds relevant securities licensing and registration typical for senior research associates in the industry, though public details on specific licenses and performance metrics are limited.

    Eric Fleming's questions to ICU MEDICAL INC/DE (ICUI) leadership

    Eric Fleming's questions to ICU MEDICAL INC/DE (ICUI) leadership • Q3 2024

    Question

    Eric Fleming of Raymond James inquired about pricing sustainability for the Plum Duo infusion system, competitive market share dynamics, the potential impact of the Mexican peso, and the resolution status of the FDA warning letter.

    Answer

    Executive Vivek Jain stated that the company is holding firm on Plum Duo pricing to reflect its technological value and feels confident in its competitive position with the Duo and upcoming Solo systems. He noted the impact of the Mexican peso is unclear but not a primary focus. Importantly, Jain confirmed a successful FDA follow-up inspection at the Minneapolis site (with no observations), a key step toward resolving the warning letter, though the final report is still pending.

    Ask Fintool Equity Research AI